Table.
Clinical efficacy, ITT, CE and ME population [N (%)]
| LZD | VAN | 95% CI** | P-value** | |
|---|---|---|---|---|
| ITT | ||||
| Global | 439/476 (92.2) | 402/454 (88.5) | −0.11, 7.47 | 0.0565 |
| EU* | 37/40 (92.5) | 34/42 (80.9) | ||
| CE | ||||
| Global | 436/462 (94.4) | 394/436 (90.4) | 0.53, 7.48 | 0.0234 |
| EU* | 37/39 (94.9) | 33/39 (84.6) | ||
| ME | ||||
| Global | 312/330 (94.5) | 278/310 (89.7) | 0.69, 9.05 | 0.0218 |
| EU* | 26/28 (92.8) | 28/33 (84.8) |
Included Portugal, Spain, and United Kingdom.
CI for global is for difference LZD - VAN, EU not sufficiently powered for analysis.